Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Haleon plc is a consumer healthcare company. The Company's product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The Company operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).

  • Revenue in GBP (TTM)9.87bn
  • Net income in GBP1.50bn
  • Incorporated2021
  • Employees22.80k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
argenx SE214.33m-741.71m18.18bn650.00------84.83-16.60-16.604.70--------383,970.70---20.19---22.8683.75---346.06-191.43---7.70----1,105.7398.1632.90--163.70--
Merck KGaA18.71bn2.98bn19.59bn63.72k22.122.724.341.057.987.9850.0865.000.45981.905.18361,073.307.365.009.246.6062.3563.1716.0012.090.858826.730.289.1612.285.5653.7513.4010.889.04
Genmab A/S1.38bn652.96m25.07bn1.56k38.458.06--18.1185.7185.71181.62408.670.4385--2.949,890,264.0020.6818.8722.6820.07----47.1742.62----0.0230.00-16.1136.10-36.7820.4450.07--
HALEON PLC9.87bn1.50bn27.05bn22.80k18.041.01--2.740.16240.16241.072.89------432,719.30--------62.76--15.68--2.85457.600.2888---3.51--21.40------
Lonza Group AG5.09bn791.52m33.01bn17.15k41.683.7726.346.4812.2141.8778.57134.940.3667----360,648.705.725.007.016.1438.6939.8215.5913.97--13.150.192431.4019.995.53-7.6717.4929.663.33
Data as of Dec 02 2022. Currency figures normalised to HALEON PLC's reporting currency: UK Pound GBX

Institutional shareholders

7.71%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Nov 2022134.43m1.46%
Dodge & Coxas of 30 Sep 2022102.46m1.11%
Franklin Mutual Advisers LLCas of 31 Oct 202294.54m1.02%
BlackRock Fund Advisorsas of 03 Nov 202292.90m1.01%
BlackRock Advisors (UK) Ltd.as of 03 Nov 202259.16m0.64%
First Eagle Investment Management LLCas of 30 Sep 202254.73m0.59%
BlackRock Investment Management (UK) Ltd.as of 31 Oct 202249.83m0.54%
TIAA-CREF Investment Management LLCas of 30 Sep 202246.15m0.50%
Vanguard Global Advisers LLCas of 31 Oct 202243.63m0.47%
Geode Capital Management LLCas of 24 Nov 202234.24m0.37%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.